Cambrex Executive and Leadership Team

Tom Loewald, the Chief Executive Officer at Cambrex, directs the overarching corporate strategy and global vision for the organization. Overseeing the integration of drug substance and drug product services, the Chief Executive Officer ensures alignment with the needs of branded and generic pharmaceutical markets. This leadership role involves driving long-term growth initiatives across North America and Europe while maintaining high standards for API and finished dosage form manufacturing. By fostering partnerships with global clients, Tom Loewald directly impacts the competitive positioning of the company within the CDMO sector. The Chief Executive Officer manages the executive team to optimize operational efficiency and service delivery. Through consistent focus on innovation and quality, Loewald secures the market reputation of the firm as a trusted partner for complex pharmaceutical development projects, ensuring the organization remains at the forefront of the industry.

Robert Green, the Executive VP & Chief Financial Officer at Cambrex, directs the financial strategy and capital allocation for the organization. Overseeing fiscal planning, reporting, and risk management, the Executive VP & Chief Financial Officer ensures the financial health necessary to support ongoing investments in drug substance technologies and facility expansions. This leadership role involves analyzing market trends to guide investment decisions in material characterization and stability storage capabilities. By maintaining robust financial controls, Robert Green directly impacts the ability of the company to pursue strategic growth opportunities in both branded and generic markets. The Executive VP & Chief Financial Officer collaborates with the board to communicate performance metrics and long-term value creation. Through disciplined financial stewardship, Green secures the resources required for the firm to maintain a competitive edge in the global CDMO landscape while supporting sustainable business development.

Richard Lifsitz, the Chief Operating Officer at Cambrex, manages the daily operational execution of manufacturing facilities and service delivery pipelines. Overseeing the production of drug substances and finished dosage forms, the Chief Operating Officer ensures that all technical capabilities, including continuous flow and solid-state science, meet rigorous quality standards. This leadership role involves optimizing supply chain logistics and manufacturing workflows across the global footprint. By streamlining internal processes, Richard Lifsitz directly supports the scalability of specialized technologies such as highly potent APIs and controlled substances. The Chief Operating Officer coordinates with site leadership to maintain operational excellence and regulatory compliance. Through meticulous oversight of production capacity and resource allocation, Lifsitz drives the efficiency required to support the diverse needs of pharmaceutical clients, ensuring that manufacturing operations consistently deliver high-quality results for complex drug development programs.

Bruno Biscaro, the President, Drug Products at Cambrex, directs the development and manufacturing of finished dosage forms. Overseeing the production of oral solids, semi-solids, liquids, and specialty forms like bi-layer tablets and stick packs, the President, Drug Products ensures that client projects meet precise formulation requirements. This leadership role involves managing the technical teams responsible for modified-release and pediatric dosage forms. By optimizing the manufacturing of sterile and non-sterile ointments, Bruno Biscaro directly impacts the ability of the company to provide comprehensive solutions across the drug lifecycle. The President, Drug Products coordinates with analytical service teams to ensure seamless transitions from development to commercial manufacturing. Through technical leadership and market-focused innovation, Biscaro drives the expansion of the drug product portfolio, ensuring that the firm remains a preferred partner for complex dosage form development and manufacturing on a global scale.

Dottie Brienza, the Chief Human Resources Officer at Cambrex, directs the talent acquisition, organizational development, and employee engagement strategies. Overseeing the cultivation of a high-performance culture, the Chief Human Resources Officer ensures that the company attracts and retains the specialized expertise required for complex drug product manufacturing. This leadership role involves designing programs that support professional growth and align the workforce with the mission of providing superior analytical services. By fostering an inclusive and innovative environment, Dottie Brienza directly impacts the operational success of the firm across its North American and European locations. The Chief Human Resources Officer manages compensation, benefits, and leadership development initiatives to ensure organizational agility. Through strategic workforce planning, Brienza supports the long-term objectives of the company, ensuring that the team possesses the necessary skills to navigate the evolving demands of the pharmaceutical industry.